MCID: SQM002
MIFTS: 46

Squamous Cell Papilloma

Categories: Cancer diseases, Oral diseases, Skin diseases

Aliases & Classifications for Squamous Cell Papilloma

MalaCards integrated aliases for Squamous Cell Papilloma:

Name: Squamous Cell Papilloma 12 15
Papilloma 43 71
Papilloma, Squamous Cell 71
Epidermoid Papilloma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:139
MeSH 43 D010212
NCIt 49 C3712
SNOMED-CT 67 63451008
UMLS 71 C0030354 C0205874

Summaries for Squamous Cell Papilloma

MalaCards based summary : Squamous Cell Papilloma, also known as papilloma, is related to skin papilloma and papillary adenoma. An important gene associated with Squamous Cell Papilloma is SNORD102 (Small Nucleolar RNA, C/D Box 102), and among its related pathways/superpathways are Cellular senescence (KEGG) and DNA Damage Response (only ATM dependent). The drugs Bethanechol and Bleomycin have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and cervix.

Wikipedia : 74 A squamous cell papilloma is a generally benign papilloma that arises from the stratified squamous... more...

Related Diseases for Squamous Cell Papilloma

Diseases related to Squamous Cell Papilloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 857)
# Related Disease Score Top Affiliating Genes
1 skin papilloma 33.6 TP53 KRT14 HRAS
2 papillary adenoma 32.9 TP53 HRAS
3 anogenital venereal wart 32.1 TP53 CDKN2A
4 penile cancer 32.1 TP53 HRAS CDKN2A
5 li-fraumeni syndrome 31.5 TP53 HRAS CDKN2A
6 suppressor of tumorigenicity 3 31.2 TP53 CDKN2A
7 cervix uteri carcinoma in situ 31.1 TP53 CDKN2A
8 papilloma 31.0 TP53 KRT14 CDKN2A
9 transitional cell carcinoma 30.6 TP53 HRAS CDKN2A
10 familial retinoblastoma 30.6 TP53 CDKN2A
11 ductal carcinoma in situ 30.4 TP53 KRT14 CDKN2A
12 in situ carcinoma 30.4 TP53 KRT14 HRAS CDKN2A
13 anus cancer 30.3 TP53 HRAS CDKN2A
14 oral leukoplakia 30.3 TP53 CDKN2A
15 vulvar intraepithelial neoplasia 30.3 TP53 CDKN2A
16 endosalpingiosis 30.2 TP53 HRAS
17 actinic keratosis 30.1 TP53 HRAS CDKN2A
18 vaginal cancer 30.1 TP53 CDKN2A
19 vulva squamous cell carcinoma 30.0 TP53 CDKN2A
20 keratosis 30.0 TP53 HRAS CDKN2A
21 anal squamous cell carcinoma 29.9 TP53 CDKN2A
22 oral squamous cell carcinoma 29.9 TP53 MIA2 HRAS CDKN2A
23 large cell acanthoma 29.9 TP53 KRT14
24 basaloid squamous cell carcinoma 29.9 TP53 KRT14 CDKN2A
25 sweat gland benign neoplasm 29.7 TP53 KRT14
26 vulva cancer 29.7 TP53 HRAS CDKN2A
27 carcinosarcoma 29.7 TP53 HRAS CDKN2A
28 esophagus verrucous carcinoma 29.7 TP53 CDKN2A
29 mucoepidermoid carcinoma 29.7 TP53 KRT14 CDKN2A
30 penile benign neoplasm 29.7 TP53 CDKN2A
31 keratinizing squamous cell carcinoma 29.7 TP53 CDKN2A
32 sebaceous adenocarcinoma 29.6 TP53 KRT14
33 tonsil cancer 29.6 TP53 KRT14 CDKN2A
34 oropharynx cancer 29.5 TP53 KRT14 HRAS CDKN2A
35 lung adenoma 29.4 TP53 HRAS CDKN2A
36 lung benign neoplasm 29.4 TP53 HRAS CDKN2A
37 skin melanoma 29.3 TP53 HRAS CDKN2A
38 pancreatitis 29.3 TP53 HRAS CDKN2A
39 adenoid cystic carcinoma 29.3 TP53 KRT14 HRAS CDKN2A
40 thymoma 29.2 TP53 HRAS CDKN2A
41 squamous cell carcinoma 29.1 TP53 MIA2 KRT14 HRAS CDKN2A
42 skin squamous cell carcinoma 28.9 TP53 KRT14 HRAS CDKN2A
43 pleomorphic adenoma 28.9 TP53 KRT14 HRAS CDKN2A
44 suppression of tumorigenicity 12 28.9 TP53 KRT14 HRAS CDKN2A
45 papilloma of choroid plexus 12.8
46 intraductal papilloma 12.6
47 esophagus squamous cell papilloma 12.5
48 squamous cell papilloma of skin 12.4
49 central breast papilloma 12.4
50 bladder transitional cell papilloma 12.4

Graphical network of the top 20 diseases related to Squamous Cell Papilloma:



Diseases related to Squamous Cell Papilloma

Symptoms & Phenotypes for Squamous Cell Papilloma

Drugs & Therapeutics for Squamous Cell Papilloma

Drugs for Squamous Cell Papilloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 241)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bethanechol Approved Phase 4 674-38-4 2370
2
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
3
Cidofovir Approved Phase 4 113852-37-2 60613
4
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
5
Polihexanide Approved, Investigational Phase 4 28757-47-3
6
Cantharidin Approved, Investigational Phase 4 56-25-7
7
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
8
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
9
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
10
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
11
Dolutegravir Approved Phase 4 1051375-16-6 54726191
12
BCG vaccine Investigational Phase 4
13
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
14 Muscarinic Agonists Phase 4
15 Anti-Bacterial Agents Phase 4
16 Antibiotics, Antitubercular Phase 4
17 Insulin, Globin Zinc Phase 4
18 insulin Phase 4
19 Chlorhexidine gluconate Phase 4
20 Hypoglycemic Agents Phase 4
21 Anti-Infective Agents, Local Phase 4
22 Disinfectants Phase 4
23 Biguanides Phase 4
24 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
25 MF59 oil emulsion Phase 4
26 Vaccines Phase 4
27
protease inhibitors Phase 4
28 Anti-Infective Agents Phase 4
29 Anti-HIV Agents Phase 4
30 HIV Protease Inhibitors Phase 4
31 Antiviral Agents Phase 4
32 Anti-Retroviral Agents Phase 4
33 Cytochrome P-450 Enzyme Inhibitors Phase 4
34 Integrase Inhibitors Phase 4
35 HIV Integrase Inhibitors Phase 4
36 Cytochrome P-450 CYP3A Inhibitors Phase 4
37
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
38
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
39
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
40
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
41
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
42
Azithromycin Approved Phase 3 83905-01-5 447043 55185
43
Promethazine Approved, Investigational Phase 3 60-87-7 4927
44
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
45
Histamine Approved, Investigational Phase 3 51-45-6 774
46
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
47
Penicillin G Approved, Vet_approved Phase 3 61-33-6 5904
48
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
49
Zinc Approved, Investigational Phase 3 7440-66-6 32051
50
Zinc sulfate Approved, Investigational Phase 3 7733-02-0

Interventional clinical trials:

(show top 50) (show all 496)
# Name Status NCT ID Phase Drugs
1 Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA Unknown status NCT02910596 Phase 4 bethanechol chloride
2 Immunogenicity Of A Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, And 18) L1 Virus-Like Particle Vaccine In Male And Female Adolescent Transplant Recipients. Unknown status NCT01101750 Phase 4
3 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
4 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Unknown status NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
5 A Phase IV, Randomised Study to Evaluate the Immune Responses of UK Adolescent Girls Receiving CervarixTM or GardasilTM Human Papillomavirus Vaccines Completed NCT00956553 Phase 4
6 Use of Cidofovir Injection in the Treatment of Recurrent Respiratory Papillomatosis." Completed NCT00205374 Phase 4 Cidofovir;Placebo
7 Antisepsis Regimen in the Surgical Treatment of Human Papilloma Virus Generated Cervical Lesions: Polyhexamethylene Biguanide Versus Chlorhexidine Completed NCT01740245 Phase 4
8 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts : a Randomized Controlled Trial Completed NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
9 Comparison of Immune Response to the Human Papillomavirus Vaccine in Young Women With and Without Inflammatory Bowel Disease Completed NCT01034358 Phase 4
10 Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine After Concomitant Vaccination in ≥50-year-old Adults Completed NCT03552445 Phase 4
11 Trichloroacetic Acid Versus Cantharone for the Treatment of Perenial Warts Completed NCT03625960 Phase 4 Cantharidin;Trichloroacetic Acid
12 Immunogenicity and Safety of MF59-adjuvanted Trivalent Influenza Vaccine (Fluad) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) in the Elderly: Single Versus Concomitant Vaccination Completed NCT02225327 Phase 4
13 Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13) and MF59-adjuvanted Influenza Vaccine (Fluad) After Concomitant Vaccination in Adults Aged ≥60 Years Completed NCT02215863 Phase 4
14 Quadrivalent HPV Vaccination After Effective Treatment of Anal Intraepithelial Neoplasia in HIV+ Men Completed NCT02087384 Phase 4 Placebo
15 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination (Version IV Dated 24Oct2017) Recruiting NCT03350698 Phase 4
16 GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose Recruiting NCT03943875 Phase 4
17 Prospective Longitudinal Study on Immunogenicity, Induction of Cellular Immune Responses and Safety of Vaccination Against HPV With the 9-valent Vaccine in HIV-positive Women (The Papillon Study) Recruiting NCT03391921 Phase 4
18 A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study Active, not recruiting NCT03180034 Phase 4
19 Immunogenicity, Compliance, Knowledge and Attitudes in Postpartum Women During a Two Dose 9-valent HPV Vaccination Series Not yet recruiting NCT04311528 Phase 4
20 A Pilot Study of the Immunogenicity of a Two-dose Protocol for 9-valent Human Papilloma Virus Vaccination in Postpartum Girls and Women (15-45 Years Old) Previously Unvaccinated Against HPV Not yet recruiting NCT04274153 Phase 4
21 Randomized, Placebo-controlled, Double-blind Study to Evaluate 2LPAPI® Efficacy on the Clearance of Genital HR-HPV Infections. Not yet recruiting NCT04232917 Phase 4 2LPAPI®;Placebo
22 The Impact of Co-infections on Inflammation in Patients Commencing Second-line Antiretroviral Therapy. A Sub-study of D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) Not yet recruiting NCT04183738 Phase 4 NRTIs;Darunavir;Ritonavir;Dolutegravir
23 A Multicenter, Randomized, Open-label Trial to Establish Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV Not yet recruiting NCT04265950 Phase 4
24 Assessment of the Safety, Side Effects and Efficacy of Interventional Cryotherapy for the Eradication of Benign Airway Disease("ICE THE BAD") Terminated NCT00747461 Phase 4
25 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
26 Evaluation of a Two-dose Schedule of Quadrivalent Human Papilloma Virus (Types 6, 11, 16, 18) Recombinant Vaccine in 11-year-old Boys in Mexico City (Gardasil® Merck and Co.). Unknown status NCT02382900 Phase 3
27 Comparison Between Tuberculin Vaccine and Cryotherapy in the Treatment of Genital Wart Patients Unknown status NCT03153566 Phase 3
28 Adjuvant Imiquimod Therapy to Reduce Recurrence Rate in Patients After Surgical Therapy of Anal HPV (Human Papilloma Virus)-Lesions Unknown status NCT03289260 Phase 3 Imiquimod 5% cream;Placebo cream
29 Phase III, Single-center Clinical Trial to Evaluate the 4-valent HPV Vaccine for the Treatment and Prevention of Recurrent Respiratory Papillomatosis in Children Unknown status NCT01995721 Phase 3
30 Efficacy Study of the Quadrivalent Human Papilloma Virus (HPV) Vaccine to Prevent Recurrence of External Genital Warts (EGW) in Patients Who Were Cured in the First Place Unknown status NCT03296397 Phase 3
31 Trial of Male Circumcision: HIV, STD and Behavioral Effects in Men, Women and the Community Unknown status NCT00124878 Phase 3
32 A Randomized, Single Blinded Trial to Evaluate the Efficacy of Imiquimod in Women With Residual/Recurrent Cervical Intraepithelial Neoplasia (CIN) After Previous Treatment Unknown status NCT02669459 Phase 3 Imiquimod
33 A Phase III Placebo-controlled Clinical Trial to Study the Tolerability, Immunogenicity and Efficacy of V501 in 16- to 26-year-old Japanese Men Completed NCT01862874 Phase 3
34 Prospective Non Controlled Study of Immunogenicity of Human Papilloma Virus (HPV) Vaccine in Groups at Special Risk of Poor Vaccine Result Completed NCT00964210 Phase 3 Licensed quadrivalent HPV vaccine, Gardasil
35 Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in Healthy Females 9 to 15 Years of Age in India Completed NCT00380367 Phase 3
36 An Immunogenicity and Safety Study of Gardasil (V501 (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine)) in Females 9 to 23 Years of Age in Korea Completed NCT00157950 Phase 3
37 A Phase III, Open-Label, Clinical Trial to Study the Safety and Immunogenicity of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 VLP Particle (VLP) Vaccine in 9- to 15-Year-Old Japanese Boys Completed NCT02576054 Phase 3
38 A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [HPV] [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus L1 Virus-Like Particle [VLP] Vaccine) in 16- to 26-year-old Men Completed NCT02114385 Phase 3
39 Randomized Trial of Immediate Treatment vs. Colposcopic Follow-up for Biopsy-Proven CIN 1 Completed NCT00156026 Phase 3
40 A Phase III Open-label, Safety, Tolerability and Immunogenicity Study of a 9-Valent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 9- to 15-Year-Old Japanese Preadolescent and Adolescent Girls Completed NCT01254643 Phase 3
41 Phase IIIb Study of Recombinant Tetravalent HPV Vaccine in Patients With Recurrent Respiratory Papillomatosis Completed NCT01375868 Phase 3
42 Immunogenicity and Safety Study of a Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years Completed NCT02562508 Phase 3
43 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region Completed NCT00017511 Phase 3 cevimeline hydrochloride
44 A PHASE II/III PILOT STUDY OF THE EFFECTS OF PROPHYLACTIC FLUCONAZOLE THERAPY ON MUCOSITIS IN PATIENTS UNDERGOING RADIATION TREATMENT FOR HEAD AND NECK CANCER Completed NCT00002533 Phase 2, Phase 3 fluconazole
45 Immunogenicity: 3 Consecutive Lots of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly at 0,1,6 Month Schedule in Healthy Females Aged 10-25 Years and Demonstrate Non-inferiority of Candidate HPV Vaccine Manufactured by Modified Production Process Completed NCT00169494 Phase 3
46 A Safety and Immunogenicity Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents and Adolescents (Base Study). A Long Term Immunogenicity, Safety, and Effectiveness Study of GARDASIL (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received GARDASIL at 9-18 Years of Age (Extension Study). Completed NCT00092547 Phase 3
47 A Phase III, Double-Blind, Randomized Study Of The Effect Of Megestrol Acetate On Weight And Health Related Quality Of Life In Head And Neck Cancer Patients Receiving Radiation Therapy Completed NCT00006799 Phase 3 megestrol acetate
48 Evaluate the Safety and Immunogenicity of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to a 0,1,6 Month Schedule in Healthy Female Subjects (10 - 14 Years) Completed NCT00196924 Phase 3
49 A Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00735462 Phase 3 2.5% imiquimod cream;3.75% imiquimod cream;Placebo cream
50 A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Amolimogene (ZYC101a) in the Treatment of High-Grade Cervical Intraepithelial Lesions (CIN 2/3) of the Uterine Cervix Completed NCT00264732 Phase 2, Phase 3 Amolimogene;Amolimogene

Search NIH Clinical Center for Squamous Cell Papilloma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


podophyllin
PODOPHYLLIN PWDR

Cochrane evidence based reviews: papilloma

Genetic Tests for Squamous Cell Papilloma

Anatomical Context for Squamous Cell Papilloma

MalaCards organs/tissues related to Squamous Cell Papilloma:

40
Breast, Skin, Cervix, Testes, T Cells, Lung, Brain

Publications for Squamous Cell Papilloma

Articles related to Squamous Cell Papilloma:

(show top 50) (show all 13992)
# Title Authors PMID Year
1
Coverage rates of the children vaccination programme in Greenland. 61
32000619 2020
2
Penile cancer with visceral metastasis and p16/human papillomavirus positivity: An unusual case of long-term survival. 61
32489901 2020
3
Prevalence of human papillomavirus in the oral cavity of an indigenous community from Southwest México. 61
32194258 2020
4
Cetuximab and Radiation Therapy Versus Cisplatin and Radiation Therapy for Locally Advanced Head and Neck Cancer: Long-Term Survival and Toxicity Outcomes of a Randomized Phase 2 Trial. 61
32184121 2020
5
RADIANCE - Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. 61
32420463 2020
6
A case of condyloma acuminate after about 30 years of urinary obstructive symptoms. 61
32322520 2020
7
A rare case of nasal Schneiderian (inverted) papilloma associated with basaloid squamous cell carcinoma. 61
32534706 2020
8
An Inverted Papilloma Arising From the Basal Lamella of the Middle Turbinate: An Endoscopic View. 61
31106584 2020
9
Frequency of Epstein-Barr virus and human papilloma virus in patients with nasopharyngeal carcinoma. 61
32170419 2020
10
Oral cancer in a 5-year-old boy: a rare case report and review of literature. 61
32312529 2020
11
Pediatric airway surgery under spontaneous respiration using high-flow nasal oxygen. 61
32302883 2020
12
INCIDENTAL FINDINGS ON BRAIN MAGNETIC RESONANCE IMAGING (MRI) IN PEDIATRIC ENDOCRINE PATIENTS. 61
32576030 2020
13
Surveillance patterns of cervical cancer patients treated with conization alone. 61
32499392 2020
14
Emerging biomarkers and clinical significance of HPV genotyping in prevention and management of cervical cancer. 61
32169490 2020
15
Woman to Woman: Implementation of a Cervical Cancer Education Training Program for Grenadian Lay Health Advisors. 61
30788676 2020
16
Modelling suggests that high human papilloma virus (HPV) vaccination coverage in combination with high uptake screening can lead to cervical cancer elimination in most low-income and lower-middle-income countries (LMICs) by the end of the century. 61
32561676 2020
17
Special Ambulatory Gynecologic Considerations in the Era of COVID-19 and Implications for Future Practice. 61
32522513 2020
18
Balancing Between Being Proactive and Neutral: School Nurses' Experiences of Offering Human Papilloma Virus Vaccination to Girls. 61
32578487 2020
19
De-intensification of treatment in human papilloma virus related oropharyngeal carcinoma: Patient choice still matters for de-escalation and for the COVID era. 61
32387030 2020
20
Identifying predictors of HPV-related head and neck squamous cell carcinoma progression and survival through patient-derived models. 61
32478869 2020
21
HPV-31 tyrosine 102 regulates interaction with E2 binding partners and episomal maintenance. 61
32493825 2020
22
Identification of novel methylation markers in HPV-associated oropharyngeal cancer: genome-wide discovery, tissue verification and validation testing in ctDNA. 61
32415241 2020
23
Impact of a single-age cohort human papillomavirus vaccination strategy in Catalonia, Spain: Population-based analysis of anogenital warts in men and women. 61
32565118 2020
24
Fetal exposure to oncoantigen elicited antigen-specific adaptive immunity against tumorigenesis. 61
32561637 2020
25
Intraoperative Human Papillomavirus Test Predicts 24-Month High-Grade Squamous Intraepithelial Lesion Recurrence Saving Costs: A Prospective Cohort Study. 61
32569022 2020
26
Pharmacovigilance Reports Received from Children and Young People, and Development of Information to Aid Future Reporting from this Age Group. 61
32253722 2020
27
Risk factors for aggressive recurrent respiratory papillomatosis in Chinese juvenile patients. 61
32491958 2020
28
Inverted papilloma of the urinary bladder shows fluorescence on photodynamic diagnosis using 5-aminolevulinic acid. 61
32311542 2020
29
[Unilateral diseases of the maxillary sinus]. 61
32556468 2020
30
Crystal structure of the catalytic C-lobe of the HECT-type ubiquitin ligase E6AP. 61
31994269 2020
31
Antiviral T Cell Receptor Complementarity Determining Region-3 Sequences Are Associated with a Worse Cancer Outcome: A Pancancer Analysis. 61
32315578 2020
32
Expression of the hippo signalling pathway effector YAP during canine epidermal tumourigenesis. 61
32155472 2020
33
CENP-50 is required for papilloma development in the two-stage skin carcinogenesis model. 61
32535988 2020
34
Curcumin Enriched VCO Protects against 7,12-Dimethyl Benz[a] Anthracene-Induced Skin Papilloma in Mice. 61
32530305 2020
35
Prediction of malignant sinonasal inverted papilloma transformation by preoperative computed tomography and magnetic resonance imaging. 61
32441707 2020
36
[Vaccination: A Double Opportunity to Prevent Human Papilloma Virus Infection]. 61
32504521 2020
37
Inverted Papilloma of the Orbit and Nasolacrimal System. 61
32501879 2020
38
Pulmonary peripheral glandular papilloma and mixed squamous cell and glandular papilloma frequently harbour the BRAF V600E mutation. 61
32096885 2020
39
Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis. 61
32344357 2020
40
Transcriptome profiling of gastric-type endocervical adenocarcinomas identifies key signaling pathways for tumor progression. 61
32317172 2020
41
The yield of pap smears and its characteristics in a community based setting in Saudi Arabia. 61
32518936 2020
42
The Relationship between Annual Airborne Pollen Levels and Occurrence of All Cancers, and Lung, Stomach, Colorectal, Pancreatic and Breast Cancers: A Retrospective Study from the National Registry Database of Cancer Incidence in Japan, 1975-2015. 61
32498416 2020
43
Adenoid cystic carcinoma of the Bartholin gland is not HPV-related: A case report and review of literature. 61
32345538 2020
44
Retrospective Study of Buccal Mucosal Salivary Neoplasms. 61
32506376 2020
45
Comparison of pain and proper sample status according to usage of tenaculum and analgesia: a randomized clinical trial. 61
32550738 2020
46
Characteristics of penile cancer in Japan: An analysis of nationwide hospital-based cancer registry data. 61
32307745 2020
47
Nonavalent human papillomavirus vaccination as alternative treatment for genital warts. 61
32500585 2020
48
Applications of a Standardized Green Tea Catechin Preparation for Viral Warts and Human Papilloma Virus-Related and Unrelated Cancers. 61
32498451 2020
49
Analysis of community-based studies related with knowledge, awareness, attitude, and behaviors towards HPV and HPV vaccine published in Turkey: A systematic review 61
31397145 2020
50
Fourth ventricle papilloma and intractable cough. 61
31745847 2020

Variations for Squamous Cell Papilloma

Cosmic variations for Squamous Cell Papilloma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM138041675 upper aerodigestive tract,larynx,other,papilloma c.140A>G p.H47R 9:21971066-21971066 0

Expression for Squamous Cell Papilloma

Search GEO for disease gene expression data for Squamous Cell Papilloma.

Pathways for Squamous Cell Papilloma

GO Terms for Squamous Cell Papilloma

Biological processes related to Squamous Cell Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intrinsic apoptotic signaling pathway GO:0097193 9.4 TP53 HRAS
2 cellular response to gamma radiation GO:0071480 9.37 TP53 HRAS
3 cell cycle arrest GO:0007050 9.33 TP53 HRAS CDKN2A
4 cell aging GO:0007569 9.32 TP53 HRAS
5 cellular senescence GO:0090398 9.26 HRAS CDKN2A
6 replicative senescence GO:0090399 8.96 TP53 CDKN2A
7 Ras protein signal transduction GO:0007265 8.8 TP53 HRAS CDKN2A

Sources for Squamous Cell Papilloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....